A study on drug innovation lag in Taiwan
, 2020 Drug lag, also known as drug innovation lag, can be categorized into marketing lag and reimbursement lag. This study investigates the trend and factors influencing drug innovation lag in Taiwan, and makes a comparison with major countries like USA ...
Cheng-Chi Chung, W.-F. Huang
openalex +2 more sources
Drug lag and associated factors of orphan drugs approved by the U.S. in China. [PDF]
Front PharmacolMo Q, He J, Guo Q, Yang Y.
europepmc +3 more sources
Pulsatile Chronotherapeutic Drug Delivery for Controlling Early Morning Surge in Blood Pressure; Effect of Coating on Eplerenone In-vitro, In-vivo Release and Urinary Na/K Ratio [PDF]
Brazilian Journal of Pharmaceutical Sciences, 2022 The objective of the present study was to develop time delayed chronotherapeutic formulation of Eplerenone (Ep) to provide rapid drug release after a pre-determined lag time for the treatment of early morning hypertension.
Maha Abd El hameed Marzouk +3 more
doaj +1 more source
Review time of oncology drugs and its underlying factors: an exploration in China
Frontiers in Pharmacology, 2023 Introduction: How the launch delay of drugs and other factors of interest can influence the length of the review period by drug agencies is still unknown, and understanding this can help better strike the trade-off related to review speed.Methods: We ...
Xingyue Zhu, Bao Liu
doaj +1 more source
Japan Works To Shorten "Drug Lag," Boost Trials of New Drugs [PDF]
JNCI Journal of the National Cancer Institute, 2010 G. Sinha
openaire +3 more sources
Oncology drug lag in Japan: has it improved over the last decade?
International Journal of Clinical Oncology, 2023 Existing studies and statistics on the drug lag between Japan and the United States (US) for anti-cancer drugs indicate that it has decreased, whereas more drugs are left unapproved in Japan. This study aimed to quantify the impact of unapproved drugs on
Yoshifumi Tachibana, M. Narukawa
semanticscholar +1 more source
Trends in oncology drug lags in Japan from 2001 to 2020: A cross‐sectional study
Clinical and Translational Science, 2023 Anticancer drugs are essential in the treatment of serious diseases, but their applications are limited by drug lags. This study investigated the characteristics of anticancer drugs approved in Japan over the past 20 years and compared the drug lag ...
Hideki Maeda +5 more
doaj +1 more source
Development of a high-throughput TR-FRET screening assay for LAG-3/FGL1 interaction
SLAS Discovery, 2023 Lymphocyte activation gene 3 (LAG-3) is a negative immune checkpoint and a key regulator of immune homeostasis with multiple biological activities related to T-cell functions.
Somaya A. Abdel-Rahman +2 more
doaj +1 more source
PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy
Frontiers in Immunology, 2022 Several clinical studies demonstrate that there exist other immune checkpoints overexpressed in some PD-1 inhibitor-resistant tumor patients. Among them, Lymphocyte-activation gene 3 (LAG-3) is one of the important immune checkpoint molecules and has ...
Ning Shi +17 more
doaj +1 more source
A Pulsatile Tablet of Famotidine Using Core in Cup Method.
Journal of Pharmacy, 2023 Introduction: The present work aims to formulate pulsatile delivery system using “core-in-cup” system for Famotidine, a H2 receptor antagonist used for duodenal ulcer, benign gastric ulcers, GERD and nocturnal acid breakthrough (A physiological ...
Shreya Ajay Rajguru +5 more
doaj +1 more source